ArticleBMC pregnancy and childbirth2026
Identifying biomarkers of the serum proteins and metabolites associated with severe preeclampsia.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPreeclampsia is a severe pregnancy-related disorder characterized by hypertension and proteinuria, and affects approximately 2–8% of pregnancies worldwide. It poses substantial risks to both maternal and fetal health, including preterm birth, intrauterine growth restriction, and life-threatening complications, such as eclampsia and organ failure. However, the mechanisms underlying preeclampsia, especially those involving blood-associated proteins, are poorly understood. This study aimed to identify critical blood proteins linked to severe preeclampsia and explore their potential mechanisms of action. MATERIALS AND
resultsTwenty-two venous blood samples (14 from patients with severe preeclampsia (sPE) and 8 from matched healthy controls) were collected for comparative proteomic analysis using advanced astral mass spectrometry. Using exploratory machine learning approaches (random forest and OPLS-DA) as feature selection tools, 36 serum proteins were identified as the sole biomarkers that exhibited significant differences between patients with sPE and healthy controls in this discovery cohort. Among these, 30 serum proteins were technically validated by PRM within the same cohort, demonstrating consistent differential expression, and could be used as potential biomarkers for sPE. Moreover, untargeted serum metabolome analysis identified 14 differential serum metabolites, including protoporphyrin IX, hecogenin, and astragalin, phenylacetylglutamine, shikimic acid, and 4,5-dihydroorotic acid, that were enriched in healthy pregnant women and patients with sPE, respectively. Changes in serum proteins were correlated with shifts in the serum metabolome in patients with sPE, suggesting potential interrelationships that warrant further investigation.
conclusionsOur research indicates that changes in serum metabolites, possibly due to the presence of serum proteins, such as ENG, may contribute to the development of sPE. This exploratory study provides preliminary insights into the interactions between serum proteins and metabolites in sPE. The findings highlight potential biomarker candidates and mechanistic pathways; however, further validation in larger cohorts is needed to confirm their diagnostic and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.